Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
Nat Med
; 24(10): 1504-1506, 2018 10.
Article
in En
| MEDLINE
| ID: mdl-30275569
ABSTRACT
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19- relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Receptors, Antigen, T-Cell
/
Drug Resistance, Neoplasm
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/
Receptors, Chimeric Antigen
Limits:
Humans
Language:
En
Journal:
Nat Med
Journal subject:
BIOLOGIA MOLECULAR
/
MEDICINA
Year:
2018
Document type:
Article
Affiliation country: